Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors on HPCs, rapidly mobilizing these cells from the bone marrow into the peripheral blood. In preclinical ...
According to the data presented at the American Society of Hematology Annual Meeting, 17 of 19 participants (89.5%) successfully collected the required number of CD34+ cells within two leukapheresis ...
Exicure (XCUR) announced results from its completed Phase 2 trial evaluating burixafor in combination with propranolol and granulocyte colony-stimulating factor for the mobilization of hematopoietic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback